Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05383001
Title Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AIO-Studien-gGmbH
Indications
Therapies
Age Groups: senior | adult
Covered Countries DEU

Facility Status City State Zip Country Details
Asklepios Fachkliniken München-Gauting Gauting 82131 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field